Brief: Black Diamond Therapeutics Says Dose Expansion Cohorts For Bdtx-1535 Phase 1 Expected To Open In 2023
April 17 (Reuters) - Black Diamond Therapeutics Inc
BDTX.O :
* BLACK DIAMOND THERAPEUTICS INC - DOSE EXPANSION COHORTS
FOR
BDTX-1535 PHASE 1 EXPECTED TO OPEN IN 2023
* BLACK DIAMOND THERAPEUTICS INC - PHASE 1 BDTX-4933
CLINICAL
STUDY EXPECTED TO INITIATE IN Q2 OF 2023
* BLACK DIAMOND THERAPEUTICS PRESENTS TRIAL IN PROGRESS
POSTER FOR
BDTX-1535 AND PRECLINICAL DATA ON BDTX-1535 AND BDTX-4933 AT THE
2023 AMERICAN ASSOCIATION OF CANCER RESEARCH ANNUAL MEETING
Further company coverage: BDTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Black Diamond Therapeutics
See all newsBlack Diamond Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Black Diamond Therapeutics Q2 net loss narrows year over year
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Black Diamond Therapeutics Q4 net loss narrows, full-year profit turns positive
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox